TIDMTRX
RNS Number : 1051P
Tissue Regenix Group PLC
05 June 2020
Tissue Regenix Group plc
Director subscriptions/PDMR dealing
Leeds, 5 June 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix", the "Company" or the "Group"), the regenerative medical
devices company, announces that following today's release of its
annual results, certain members of the Board have conditionally
subscribed for a total of GBP620,000 (the "Subscription"). The
Subscription was highlighted in the Company's recent equity
fundraising, further details of which were first announced on 21
May 2020 (the "Fundraise").
The Subscription will result in the issue and allotment of a
total of 248,000,000 new ordinary shares in the Company and is
being carried out at the same issue price of 0.25p and on identical
terms as those of the Fundraise.
Director subscriptions
The following Directors have conditionally subscribed for shares
in the Company in the amounts set out in the table below:
Director Current % of Existing Subscription Holding post % of Enlarged
Holding Ordinary Fundraise Share Capital
Shares
Jonathan
Martin Glenn
(Interim
Chair) 600,000 0.05 % 40,000,000 40,600,000 0.58%
Randeep Singh
Grewal (NED) 0 0 % 90,000,000 90,000,000 1.28 %
Alan Jonathan
Richard Miller
(NED) 22,886,988 1.95% 94,000,000 116,886,988 1.67 %
Gareth Hywel
Jones (Interim
CEO) 0 0 % 24,000,000 24,000,000 0.34 %
Total 23,486,988 2 % 248,000,000 271,486,988 3.87 %
The participation by Jonathan Glenn, Randeep Grewal, Alan Miller
and Gareth Jones in the Fundraising constitutes a related party
transaction for the purposes of the AIM Rules. The Independent
Director, being Shervanthi Homer-Vanniasinkam, having consulted
with the Company's nominated adviser, Stifel, consider that the
terms of the related party transaction are fair and reasonable
insofar as shareholders are concerned.
General meeting and importance of the vote
The Subscription and wider Fundraise is conditional on, amongst
other things, the passing of the Placing Resolutions to be proposed
at a general meeting to be held at the offices of Squire Patton
Boggs (UK) LLP, 6 Wellington Place, Leeds at 12 p.m. on 9 June 2020
(the "General Meeting").
Unless otherwise defined, capitalised words used in this notice
have the meanings given to them in the Proposed Equity Fundraise
regulatory announcement, as released on 21 May 2020.
For more Information:
Tissue Regenix Group plc
Caitlin Pearson, Head of Communications Tel: 0330 430 3073
--------------------------------------------- ---------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- ---------------------
FTI Consulting Tel: 0203 727 1000
Simon Conway / Victoria Foster Mitchell
/ Mary Whittow
============================================= =====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities ("PDMRs") and persons
closely associated ("PCA") with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Names Jonathan Martin Glenn
------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Interim Chair
------------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Tissue Regenix Group plc
------------------------- ----------------------------------------
b) LEI 213800PNOD5UHQUFJI36
------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Ordinary Shares of 0.1p
of the financial
instrument,
type of instrument
------------------------- ----------------------------------------
b) Identification GB00B5SGVL29
code
------------------------- ----------------------------------------
c) Nature of the Subscription for Ordinary Shares
transaction
------------------------- ----------------------------------------
d) Price(s) and Volume(s):
volume(s) 40,000,000 Ordinary Shares
Price: 0.25 pence per Ordinary Share
------------------------- ----------------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
------------------------- ----------------------------------------
e) Date of the 5 June 2020
transactions
------------------------- ----------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Names Randeep Singh Grewal
------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status NED
------------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Tissue Regenix Group plc
------------------------- ----------------------------------------
b) LEI 213800PNOD5UHQUFJI36
------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Ordinary Shares of 0.1p
of the financial
instrument,
type of instrument
------------------------- ----------------------------------------
b) Identification GB00B5SGVL29
code
------------------------- ----------------------------------------
c) Nature of the Subscription for Ordinary Shares
transaction
------------------------- ----------------------------------------
d) Price(s) and Volume(s):
volume(s) 90,000,000 Ordinary Shares
Price: 0.25 pence per Ordinary Share
------------------------- ----------------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
------------------------- ----------------------------------------
e) Date of the 5 June 2020
transactions
------------------------- ----------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Names Alan Jonathan Richard Miller
------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status NED
------------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Tissue Regenix Group plc
------------------------- ----------------------------------------
b) LEI 213800PNOD5UHQUFJI36
------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Ordinary Shares of 0.1p
of the financial
instrument,
type of instrument
------------------------- ----------------------------------------
b) Identification GB00B5SGVL29
code
------------------------- ----------------------------------------
c) Nature of the Subscription for Ordinary Shares
transaction
------------------------- ----------------------------------------
d) Price(s) and Volume(s):
volume(s) 94,000,000 Ordinary Shares
Price: 0.25 pence per Ordinary Share
------------------------- ----------------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
------------------------- ----------------------------------------
e) Date of the 5 June 2020
transactions
------------------------- ----------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Names Gareth Hywel Jones
------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Interim CEO
------------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Tissue Regenix Group plc
------------------------- ----------------------------------------
b) LEI 213800PNOD5UHQUFJI36
------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Ordinary Shares of 0.1p
of the financial
instrument,
type of instrument
------------------------- ----------------------------------------
b) Identification GB00B5SGVL29
code
------------------------- ----------------------------------------
c) Nature of the Subscription for Ordinary Shares
transaction
------------------------- ----------------------------------------
d) Price(s) and Volume(s):
volume(s) 24,000,000 Ordinary Shares
Price: 0.25 pence per Ordinary Share
------------------------- ----------------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
------------------------- ----------------------------------------
e) Date of the 5 June 2020
transactions
------------------------- ----------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHVELBBBQLBBBB
(END) Dow Jones Newswires
June 05, 2020 04:15 ET (08:15 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024
